Yang M, Ding X, Murray PA. Differential effects of intravenous anesthetics on capacitative calcium entry in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 294: L1007-L1012, 2008. First published March 14, 2008 doi:10.1152/ajplung.00171.2007We assessed the roles of the protein kinase C (PKC) and the tyrosine kinase (TK) signaling pathways in regulating capacitative calcium entry (CCE) in human pulmonary artery smooth muscle cells (PASMCs) and investigated the effects of intravenous anesthetics (midazolam, propofol, thiopental, ketamine, etomidate, morphine, and ]i; i.e., CCE was stimulated in human PASMCs. PKC activation attenuated (P Ͻ 0.05), whereas PKC inhibition potentiated (P Ͻ 0.05), both peak and sustained CCE. TK inhibition attenuated (P Ͻ 0.05) both peak and sustained CCE. Midazolam, propofol, and thiopental each attenuated (P Ͻ 0.05) both peak and sustained CCE, whereas ketamine, etomidate, morphine, and fentanyl had no effect on CCE. Our results suggest that CCE in human PASMCs is influenced by both the TK and PKC signaling pathways. Midazolam, propofol, and thiopental each attenuated CCE, whereas ketamine, etomidate, morphine, and fentanyl had no effect on CCE.
-We assessed the roles of the protein kinase C (PKC) and the tyrosine kinase (TK) signaling pathways in regulating capacitative calcium entry (CCE) in human pulmonary artery smooth muscle cells (PASMCs) and investigated the effects of intravenous anesthetics (midazolam, propofol, thiopental, ketamine, etomidate, morphine, and fentanyl) on CCE in human PASMCs. Fura-2-loaded human PASMCs were placed in a dish (37°C) on an inverted fluorescence microscope. Intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) was measured as the 340/380 fluorescence ratio in individual PASMCs. Thapsigargin, a sarcoplasmic reticulum Ca 2ϩ -adenosine triphosphatase inhibitor, was used to deplete intracellular Ca 2ϩ stores after removing extracellular Ca 2ϩ . CCE was then activated by restoring extracellular Ca 2ϩ (2.2 mM). The effects of PKC activation and inhibition, TK inhibition, and the intravenous anesthetics on CCE were assessed. Thapsigargin caused a transient increase in [Ca 2ϩ ]i. Restoring extracellular Ca 2ϩ caused a rapid peak increase in [Ca 2ϩ ]i, followed by a sustained increase in [Ca 2ϩ ]i; i.e., CCE was stimulated in human PASMCs. PKC activation attenuated (P Ͻ 0.05), whereas PKC inhibition potentiated (P Ͻ 0.05), both peak and sustained CCE. TK inhibition attenuated (P Ͻ 0.05) both peak and sustained CCE. Midazolam, propofol, and thiopental each attenuated (P Ͻ 0.05) both peak and sustained CCE, whereas ketamine, etomidate, morphine, and fentanyl had no effect on CCE. Our results suggest that CCE in human PASMCs is influenced by both the TK and PKC signaling pathways. Midazolam, propofol, and thiopental each attenuated CCE, whereas ketamine, etomidate, morphine, and fentanyl had no effect on CCE.
protein kinase C; tyrosine kinase INTRAVENOUS ANESTHETICS ARE widely used in anesthetic practice as premedicants, induction agents, or main anesthetics in total intravenous anesthesia. In general, intravenous anesthetic agents have been shown to exert a pulmonary vasodilator influence (24, 28) . Modulation of intracellular calcium concentration ([Ca 2ϩ ] i ) is a key factor in the regulation of vascular smooth muscle tone. Capacitative calcium entry (CCE) is activated by depletion of intracellular Ca 2ϩ stores (3, 27) . It is a critical mechanism for refilling intracellular Ca 2ϩ stores and maintaining a sustained increase in [Ca 2ϩ ] i (5, 20) . CCE is a possible cellular target for anesthetic agents that alter vascular smooth muscle tone (11) . CCE has been demonstrated in human pulmonary artery smooth muscle cells (HPASMCs) (16) , although the mechanism by which CCE regulates vascular smooth muscle tone in HPASM is unknown. Moreover, the effects of intravenous anesthetics on CCE have not been elucidated.
We have previously demonstrated that the protein kinase C (PKC) and tyrosine kinase (TK) signaling pathways are involved in CCE in canine PASMCs (11, 18) , whereas only TK is involved in CCE in canine pulmonary venous smooth muscle cells (PVSMCs) (30) . Moreover, we have reported that intravenous anesthetics attenuate CCE via the PKC signaling pathway in canine PASMCs (18) and via the TK signaling pathway in canine PVSMCs (30) . The goal of the current study was to investigate the effects of intravenous anesthetics on CCE in HPASMCs and to assess the roles of the PKC and TK signaling pathways in regulating CCE.
MATERIALS AND METHODS
All procedures were approved by the Cleveland Clinic Institutional Animal Care and Use Committee (Cleveland, OH).
Cell culture of HPASMCs. To initiate cultures, cryopreserved HPASMCs (Cascade Biologics, Portland, OR) were thawed and inoculated in 25-cm 2 culture flasks (Becton Dickinson Labware, Franklin Lakes, NJ). Cells were nourished by Medium 231(Cascade Biologics) containing Smooth Muscle Growth Supplement (Cascade Biologics) and antibiotic mixture solution (10,000 U/ml penicillin and 10,000 g/ml streptomycin; Life Technologies, Rockville, MD). Cells were kept in a humidified atmosphere of 5% CO 2-95% air at 37°C and were allowed to proliferate for 7-10 days until confluence was achieved. Cells were then subcultured to 35-mm culture dishes specially designed for fluorescence microscopy (Bioptechs ⌬T System, Butler, PA) and used for experimentation within 72 h after subculture. Cells from the third passage were used for experiments.
Fura-2 loading procedure. Twenty-four hours before experimentation, the culture medium containing 10% fetal bovine serum was replaced with serum-free medium to arrest cell growth, allow for establishment of steady-state cellular events independent of cell division, and to prevent a false estimate of [Ca 2ϩ ]i resulting from binding of available dye to serum protein in the medium. HPASMCs were loaded with the acetoxymethyl ester form of fura-2 (fura-2-AM: 2 M) at ambient temperature. After the 30-min loading period, the cells were washed twice in Krebs-Ringer buffer, which contained 125 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4, 11 mM glucose, 2.5 mM CaCl 2, and 25 mM HEPES, at pH 7.40 adjusted with NaOH at ambient temperature for an additional 20 min before initiating the study. This provided enough time to wash away any extracellular fura-2-AM and for intracellular esterases to cleave fura-2-AM into the active fura-2.
Determination of intracellular free calcium concentration. Culture dishes containing fura-2-loaded HPASMCs were placed in a temperature-regulated (37°C) chamber (Bioptechs) mounted on the stage of an Olympus IX-70 inverted fluorescence microscope (Olympus America, Lake Success, NY). Fluorescence measurements were performed on individual HPASMCs in a cultured monolayer using a dual wavelength spectrofluorometer (Deltascan RFK6002; Photon Tech-nology International, So. Brunswick, NJ) at excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. The volume of the chamber was 1.5 ml. The cells were bathed with Krebs-Ringer buffer. The temperature of all solutions was maintained at 37°C in a water bath. Solution changes were accomplished rapidly by aspirating the buffer in the dish and infusing new solution. Just before data acquisition, background fluorescence (i.e., fluorescence between cells) was measured and subtracted automatically from the subsequent experimental measurements. Fura-2 fluorescence signals (340, 380, and 340/380 ratio) originating from single HPASMCs were continuously monitored at a sampling frequency of 25 Hz and were collected using a software package from Photon Technology International. [Ca 2ϩ ]i was measured as the 340/380 fluorescence ratio in individual HPASMCs.
Experimental protocols. Thapsigargin (1 M), a sarcoplasmic reticulum (SR) Ca 2ϩ -ATPase inhibitor (33) , was used to deplete intracellular Ca 2ϩ stores after removing extracellular Ca 2ϩ . CCE was induced when extracellular Ca 2ϩ (2.2 mM) was restored. Any given HPASMC was exposed to only one agent. The effects of L-type voltage-dependent Ca 2ϩ channel inhibition (nifedipine: 10 M), nonselective Ca 2ϩ channel inhibition (SKF-96365: 50 M), TK inhibition (Tyrphostin 23: 100 M), PKC activation (phorbol 12-myristate 13-acetate; PMA, 1 M), and PKC inhibition (bisindolylmaleimide 1; BIS1, 1 M) on CCE were investigated. The concentration of each inhibitor was chosen based on previous experience in PASMCs (11, 18) and PVSMCs (9, 10) . The effects of intravenous anesthetics [midazolam (100 M), propofol (100 M), thiopental (100 M), ketamine (100 M), etomidate (100 M), morphine (100 M), and fentanyl (1 M)] on CCE were also assessed.
Reagents. Midazolam and morphine were purchased from Baxter Healthcare (Deerfield, IL). Tyrphostin 23, thiopental, thapsigargin, and nifedipine were obtained from Sigma Chemical (St. Louis, MO), propofol from Aldrich (Milwaukee, WI), ketamine from Fort Dodge Animal Health (Fort Dodge, IA), and etomidate and fentanyl from Abbott Laboratories (N. Chicago, IL). BIS1, PMA, and SKF-96365 were obtained from Calbiochem (La Jolla, CA), and fura-2-AM was purchased from Teflabs (Austin, TX). Etomidate, fentanyl, ketamine, midazolam, and morphine were dissolved in distilled water as stock solutions. BIS1, fura-2-AM, nifedipine, propofol, PMA, SKF-96365, thapsigargin, and Tyrphostin 23 were dissolved in DMSO (Sigma Chemical) as stock solutions. Aliquots of each stock solution were diluted 1:1,000 in Krebs-Ringer buffer to achieve final concentrations. Similar dilutions of DMSO in Krebs-Ringer buffer had no effect on [Ca 2ϩ ]i (10). Pure propofol was used to avoid any effects of the intralipid emulsion on the fluorescence signal.
Data analysis. The peak and sustained 340/380 fluorescence signals were measured when the solution was switched from a Ca 2ϩ -free solution to a solution containing 2.2 mM Ca 2ϩ . Triplicate CCE responses were measured in each cell. The peak ratio was obtained by reading the highest point of the trace. The sustained ratio was obtained by averaging the fluorescence values measured 5 min after reintroduction of the Ca 2ϩ -containing solution. The change in the 340/380 fluorescence ratio was then calculated by subtracting the resting ratio value (baseline) of each intervention. Changes in the peak and sustained ratio in response to the agents are expressed as percent of control. The control response was the first CCE response in each cell, and this value was set at 100%. Data are expressed as means Ϯ SE. Statistical analysis utilized repeated measures analysis of variance and Student's t-test for intra-and intergroup comparison, respectively. Differences were considered statistically significant at P Ͻ 0.05. (Fig. 1A) . To assess the reproducibility of inducing CCE in the same HPASMC, extracellular Ca 2ϩ was sequentially removed and restored three consecutive times in the continued presence of thapsigargin. There were no significant differences in the peak or sustained increases in [Ca 2ϩ ] i between the first and the second CCE, but the third CCE was slightly smaller (P Ͻ 0.05) in magnitude in the peak and sustained increases in [Ca 2ϩ ] i compared with the first CCE (Fig. 1B) . In all subsequent experiments, the second CCE response in paired untreated HPASMCs was compared with the second CCE response in HPASMCs pretreated with either an inhibitor, an activator, or an intravenous anesthetic.
RESULTS
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Effect of voltage-operated Ca 2ϩ channel inhibition on CCE. Nifedipine was used to inhibit voltage-dependent Ca 2ϩ channels. Nifedipine (10 M) was applied 5 min before [Ca 2ϩ ] o was restored the second time ( Fig. 2A) . As expected, nifedipine had no effect on the peak or sustained increases in [Ca 2ϩ ] i due to CCE (Fig. 2B) .
Effect of receptor-operated Ca 2ϩ channel inhibition on CCE. SKF-96365 is a nonselective Ca 2ϩ channel inhibitor that has been used by many investigators to inhibit CCE (34) . SKF-96365 (50 M) was applied 5 min before [Ca 2ϩ ] o was restored the second time (Fig. 3A) . SKF-96365 attenuated (P Ͻ 0.05) peak and sustained CCE by 79 Ϯ 2% and 73 Ϯ 2%, respectively (Fig. 3B) .
Effects of PKC activation and inhibition on CCE. PMA (1 M) and BIS1 (1 M) were used to activate and inhibit PKC, respectively. They were applied 5 min before [Ca 2ϩ ] o was restored the second time. The PKC activator PMA (1 M) attenuated (P Ͻ 0.05) peak and sustained CCE (Fig. 4A) , whereas PKC inhibition with BIS1 (1 M) slightly potentiated (P Ͻ 0.05) peak and sustained CCE (Fig. 4B) .
Effect of TK inhibition on CCE. Tyrphostin 23 was used to inhibit TK. Tyrphostin 23 (100 M) was applied 5 min before [Ca 2ϩ ] o was restored the second time. Tyrphostin 23 attenuated (P Ͻ 0.05) peak and sustained CCE (Fig. 5) .
Effects of intravenous anesthetics on CCE. The intravenous anesthetics were applied 15 min before [Ca 2ϩ ] o was restored the second time. Midazolam (100 M), propofol (100 M), and thiopental (100 M) each attenuated (P Ͻ 0.05) both peak and sustained CCE (Fig. 6 ). However, ketamine (100 M), etomidate (100 M), morphine (100 M), and fentanyl (1 M) each failed to attenuate peak or sustained CCE ( Fig. 7 and 8 ).
DISCUSSION
The main findings of this study are as follows. First, both PKC and TK are involved in the signal transduction pathway for CCE in HPASMCs. The TK signaling pathway positively regulates CCE, whereas PKC negatively regulates CCE. Second, intravenous anesthetics have differential effects on CCE. Midazolam, thiopental, and propofol attenuate CCE, whereas ketamine, etomidate, morphine, and fentanyl have no effect on CCE.
Regulation release triggers Ca 2ϩ influx though store-operated Ca 2ϩ channels in the plasma membrane, namely CCE (26) . Therefore, CCE is a mechanism that links [Ca 2ϩ ] SR (calcium concentration in the sarcoplasmic reticulum) to membrane Ca 2ϩ permeability (5, 20) and serves as an important pathway to refill intracellular Ca 2ϩ stores and maintain sustained Ca 2ϩ influx (20) . In the current study, thapsigargin was used as a tool to deplete the SR pool of Ca 2ϩ in the absence of extracellular Ca 2ϩ and thereby activate CCE. Consistent with our previous studies (18, 30) , the amplitude of the thapsigargin-induced increase in [Ca 2ϩ ] i was variable, which likely reflects differ- entry through both voltage-operated calcium channels (VOCCs) and store-operated calcium channels (SOCCs); the relative contribution of each depends on the smooth muscle type (14) , with SOCCs appearing to be of greater importance in tonic smooth muscle, such as found in the gastric fundus and pulmonary artery (14) . In this study, the L-type VOCC blocker, nifedipine, had no effect on CCE, whereas SKF-96365 markedly attenuated both the peak and sustained increases in [Ca 2ϩ ] i due to CCE. These results suggest that CCE is insensitive to voltage-gated Ca 2ϩ channel inhibitors in HPASMCs. The mechanism linking store depletion to the opening of SOCCs remains elusive. It might involve the generation of a diffusible chemical messenger or a direct protein-protein interaction between the SR and the plasma membrane (14) . It is well established that PKC regulates many aspects of Ca 2ϩ signaling. These include inhibition of IP 3 production (4, 13, 17) , thereby inhibiting hormone-dependent Ca 2ϩ release and facilitation (6, 25) or inhibition (21, 22, 25) of CCE. In the present study, activation of PKC with PMA attenuated both peak and sustained CCE. In contrast, PKC inhibition with BIS1 potentiated both peak and sustained CCE. Thus, PKC negatively regulates CCE in HPASMCs.
Besides PKC, tyrosine phosphorylation has been reported to modulate CCE in a variety of cells (11, 21, 22, 29, 30) . It has been reported that depletion of intracellular Ca 2ϩ stores triggers tyrosine phosphorylation (29) , and inhibition of TK attenuates CCE in a number of cell types (2, 32) , including smooth muscle (8) . We have demonstrated that inhibition of TK attenuates CCE in canine PASMCs and PVSMCs (18, 30) . Consistent with these previous studies, the TK inhibitor Tyrphostin 23 attenuated CCE in HPASMCs. This suggests that the TK signaling pathway is involved in CCE in HPASMCs. Together, these results suggest that CCE in HPASMCs involves both PKC and TK pathways.
Two studies have investigated CCE in HPASMCs (15, 19 ] i and vasomotor tone in PASMCs (11), the ion channel associated Fig. 7 . A: summarized data showing that ketamine (100 M) had no effect on CCE (n ϭ 11 cells). B: summarized data showing that etomidate (100 M) had no effect on CCE (n ϭ 8 cells). Fig. 8 . A: summarized data showing that morphine (100 M) had no effect on CCE (n ϭ 6 cells). B: summarized data showing that fentanyl (1 M) had no effect on CCE (n ϭ 7 cells).
with CCE may serve as a cellular target for intravenous anesthetics. We previously demonstrated that propofol attenuated CCE in canine PASMCs via a PKC-dependent mechanism (18) , and thiopental, midazolam, and ketamine each attenuated CCE in canine PVSMCs via a TK-dependent mechanism (30) . However, the effects of intravenous anesthetics on CCE in human pulmonary arterial smooth muscle have not been investigated. In the present study, midazolam, propofol, and thiopental each attenuated CCE, whereas etomidate, ketamine, morphine, and fentanyl had no effect on CCE in HPASMCs. The cellular target for the intravenous anesthetics-induced attenuation of CCE remains to be elucidated, although possible mechanisms could involve inhibition of expression of TRP, as well as the PKC and/or TK signaling pathways.
We acknowledge that results obtained from this in vitro study can only be cautiously extrapolated to clinical practice. However, because CCE is an important mechanism for regulating vascular smooth muscle contraction, our results provide new insight concerning the effects of intravenous anesthetics on human pulmonary arterial smooth muscle contraction. CCE should be considered as a possible cellular target for anesthetic agents that alter vascular smooth muscle tone.
In summary, CCE exists in HPASMCs. The PKC signaling pathway negatively regulates CCE, whereas the TK signaling pathway positively regulates CCE. Midazolam, propofol, and thiopental each attenuate CCE, whereas ketamine, etomidate, morphine, and fentanyl had no effect on CCE in HPASMCs. We will investigate the cellular mechanism by which the intravenous anesthetics attenuated CCE in HPASMCs in future studies.
